[{"id":"dddae553-9ce4-4728-9047-032010347ec6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07471776","created_at":"2026-03-28T01:44:37.396Z","updated_at":"2026-03-28T01:44:37.396Z","phase":"Phase 2","brief_title":"Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","source_id_and_acronym":"NCT07471776","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy) • Datroway (datopotamab deruxtecan-dlnk) • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/11/2026","start_date":" 03/11/2026","primary_txt":" Primary completion: 03/11/2028","primary_completion_date":" 03/11/2028","study_txt":" Completion: 03/11/2029","study_completion_date":" 03/11/2029","last_update_posted":"2026-03-13"},{"id":"5ca3f586-5d57-495c-9088-bac9d19c4782","acronym":"","url":"https://clinicaltrials.gov/study/NCT04826341","created_at":"2021-04-01T16:52:34.686Z","updated_at":"2025-02-25T13:40:26.267Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","source_id_and_acronym":"NCT04826341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-21"},{"id":"ce9dfb12-840f-46f6-b8d1-947639822665","acronym":"Morpheus Lung","url":"https://clinicaltrials.gov/study/NCT03337698","created_at":"2021-01-18T16:29:17.212Z","updated_at":"2025-02-25T13:48:26.615Z","phase":"Phase 1/2","brief_title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","source_id_and_acronym":"NCT03337698 - Morpheus Lung","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-20"},{"id":"a5c52f3d-d931-4d6c-a0fc-d7a329637aae","acronym":"ADAPT-TN-III","url":"https://clinicaltrials.gov/study/NCT06081244","created_at":"2023-10-14T01:13:01.938Z","updated_at":"2025-02-25T15:20:56.304Z","phase":"Phase 2","brief_title":"NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)","source_id_and_acronym":"NCT06081244 - ADAPT-TN-III","lead_sponsor":"West German Study Group","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 348","initiation":"Initiation: 10/10/2024","start_date":" 10/10/2024","primary_txt":" Primary completion: 09/01/2029","primary_completion_date":" 09/01/2029","study_txt":" Completion: 09/01/2029","study_completion_date":" 09/01/2029","last_update_posted":"2025-02-12"},{"id":"f6a27acf-7978-4c4b-a907-56c547d54b2a","acronym":"Morpheus-TNBC","url":"https://clinicaltrials.gov/study/NCT03424005","created_at":"2021-01-18T16:53:25.262Z","updated_at":"2025-02-25T15:17:38.740Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT03424005 - Morpheus-TNBC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PD-L1 • PIK3CA","pipe":" | ","alterations":" PD-L1 expression • PIK3CA mutation","tags":["HER-2 • PD-L1 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)"],"overall_status":"Recruiting","enrollment":" Enrollment 580","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 05/03/2028","primary_completion_date":" 05/03/2028","study_txt":" Completion: 05/03/2028","study_completion_date":" 05/03/2028","last_update_posted":"2025-02-10"},{"id":"3fd4e005-f66e-41a9-982d-62459a2e84ea","acronym":"NCI-2018-01581","url":"https://clinicaltrials.gov/study/NCT03606967","created_at":"2021-01-18T17:43:57.034Z","updated_at":"2025-02-25T16:37:09.345Z","phase":"Phase 2","brief_title":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03606967 - NCI-2018-01581","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PD-L1 negative","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • Imjudo (tremelimumab-actl) • Trodelvy (sacituzumab govitecan-hziy) • Hiltonol (poly-ICLC) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 04/13/2021","start_date":" 04/13/2021","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-07"},{"id":"08f4f7cb-1de9-4017-ba99-77f7d20628d0","acronym":"ARTS-021-1001","url":"https://clinicaltrials.gov/study/NCT05867251","created_at":"2023-05-19T13:05:01.323Z","updated_at":"2025-02-25T16:46:48.865Z","phase":"Phase 1/2","brief_title":"Study of AVZO-021 in Patients with Advanced Solid Tumors","source_id_and_acronym":"NCT05867251 - ARTS-021-1001","lead_sponsor":"Avenzo Therapeutics, Inc.","biomarkers":" HER-2 • CCNE1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CCNE1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • carboplatin • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • Trodelvy (sacituzumab govitecan-hziy) • AVZO-021"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 08/30/2023","start_date":" 08/30/2023","primary_txt":" Primary completion: 01/31/2028","primary_completion_date":" 01/31/2028","study_txt":" Completion: 01/31/2030","study_completion_date":" 01/31/2030","last_update_posted":"2025-02-05"},{"id":"fd07330d-4021-4953-a335-77bf14292062","acronym":"ASCENT-05","url":"https://clinicaltrials.gov/study/NCT05633654","created_at":"2022-12-01T15:57:14.884Z","updated_at":"2025-02-25T17:31:43.714Z","phase":"Phase 3","brief_title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)","source_id_and_acronym":"NCT05633654 - ASCENT-05","lead_sponsor":"Gilead Sciences","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • capecitabine • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 1514","initiation":"Initiation: 12/12/2022","start_date":" 12/12/2022","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 08/01/2031","study_completion_date":" 08/01/2031","last_update_posted":"2025-01-30"},{"id":"e0140ec6-c75d-43bd-8e7c-53aed0cb1b56","acronym":"WIN-B","url":"https://clinicaltrials.gov/study/NCT06612203","created_at":"2025-02-25T18:45:57.055Z","updated_at":"2025-02-25T18:45:57.055Z","phase":"Phase 1/2","brief_title":"Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT06612203 - WIN-B","lead_sponsor":"MedSIR","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy) • zedoresertib (Debio 0123)"],"overall_status":"Recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 01/17/2025","start_date":" 01/17/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-01-24"},{"id":"db660b09-0f52-4a82-9f38-79007e8d5211","acronym":"MORPHEUS mUC","url":"https://clinicaltrials.gov/study/NCT03869190","created_at":"2021-01-18T19:04:50.965Z","updated_at":"2025-02-25T13:18:52.965Z","phase":"Phase 1/2","brief_title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","source_id_and_acronym":"NCT03869190 - MORPHEUS mUC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • gemcitabine • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (ONO-7913) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • RG7827 • lomvastomig (RG7769)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 06/01/2019","start_date":" 06/01/2019","primary_txt":" Primary completion: 10/03/2024","primary_completion_date":" 10/03/2024","study_txt":" Completion: 05/21/2026","study_completion_date":" 05/21/2026","last_update_posted":"2025-01-03"},{"id":"de2401e1-5d7d-4d66-a7ff-49b260d21b77","acronym":"ASCENT-04","url":"https://clinicaltrials.gov/study/NCT05382286","created_at":"2022-05-19T11:56:14.579Z","updated_at":"2025-02-25T16:17:43.197Z","phase":"Phase 3","brief_title":"Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05382286 - ASCENT-04","lead_sponsor":"Gilead Sciences","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 443","initiation":"Initiation: 07/25/2022","start_date":" 07/25/2022","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-12-24"},{"id":"829b11a8-2149-49a1-8445-bba09c622fc3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06739395","created_at":"2025-02-26T09:10:09.582Z","updated_at":"2025-02-26T09:10:09.582Z","phase":"Phase 2","brief_title":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","source_id_and_acronym":"NCT06739395","lead_sponsor":"Tianjin Medical University Second Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Focus V (anlotinib) • temozolomide • Lenvima (lenvatinib) • Piqray (alpelisib) • pazopanib • Epidaza (chidamide) • Trodelvy (sacituzumab govitecan-hziy) • vebreltinib (APL-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/01/2024","start_date":" 11/01/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-12-18"},{"id":"0983518d-a48f-44db-87f7-0f334b50208a","acronym":"Saci-IO TNBC","url":"https://clinicaltrials.gov/study/NCT04468061","created_at":"2021-01-18T21:28:18.947Z","updated_at":"2025-02-25T16:10:30.435Z","phase":"Phase 2","brief_title":"Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC","source_id_and_acronym":"NCT04468061 - Saci-IO TNBC","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PD-L1 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/20/2020","start_date":" 07/20/2020","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2024-09-19"},{"id":"50d017e4-c038-44db-850c-687452cadcfc","acronym":"Saci-IO HR+","url":"https://clinicaltrials.gov/study/NCT04448886","created_at":"2021-01-18T21:24:20.750Z","updated_at":"2025-02-25T16:10:28.010Z","phase":"Phase 2","brief_title":"Sacituzumab Govitecan +/- Pembrolizumab in HR+ / HER2 - MBC","source_id_and_acronym":"NCT04448886 - Saci-IO HR+","lead_sponsor":"Ana C Garrido-Castro, MD","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 03/09/2024","primary_completion_date":" 03/09/2024","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-09-10"},{"id":"1c9daf03-acbe-412b-99d6-f63aac6d1d20","acronym":"EVER-132-002","url":"https://clinicaltrials.gov/study/NCT04639986","created_at":"2021-01-19T20:38:27.058Z","updated_at":"2024-07-02T16:34:26.121Z","phase":"Phase 3","brief_title":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","source_id_and_acronym":"NCT04639986 - EVER-132-002","lead_sponsor":"Gilead Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 331","initiation":"Initiation: 11/23/2020","start_date":" 11/23/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-14"},{"id":"f9f357c2-8949-408a-8e82-24a82b424f06","acronym":"EVER-132-003","url":"https://clinicaltrials.gov/study/NCT05119907","created_at":"2023-03-03T17:01:47.232Z","updated_at":"2024-07-02T16:34:25.825Z","phase":"Phase 2","brief_title":"Study of Sacituzumab Govitecan in Patients With Solid Tumor","source_id_and_acronym":"NCT05119907 - EVER-132-003","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 10/12/2021","start_date":" 10/12/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-06-14"},{"id":"5f860286-e6e3-44bc-a0d0-5065d0478838","acronym":"ASCENT-03","url":"https://clinicaltrials.gov/study/NCT05382299","created_at":"2022-05-19T11:56:14.957Z","updated_at":"2024-07-02T16:34:26.679Z","phase":"Phase 3","brief_title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05382299 - ASCENT-03","lead_sponsor":"Gilead Sciences","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 540","initiation":"Initiation: 07/20/2022","start_date":" 07/20/2022","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-06-12"},{"id":"d2c7cab5-d05e-40cb-8ce7-9e53c41d486a","acronym":"KEYNOTE D46","url":"https://clinicaltrials.gov/study/NCT05609968","created_at":"2022-11-08T14:56:43.032Z","updated_at":"2024-07-02T16:34:27.530Z","phase":"Phase 3","brief_title":"Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)","source_id_and_acronym":"NCT05609968 - KEYNOTE D46","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 614","initiation":"Initiation: 02/06/2023","start_date":" 02/06/2023","primary_txt":" Primary completion: 01/12/2027","primary_completion_date":" 01/12/2027","study_txt":" Completion: 08/23/2028","study_completion_date":" 08/23/2028","last_update_posted":"2024-06-11"},{"id":"607d2950-c677-467b-8196-ea2b0e2b9d8e","acronym":"VELOCITY-Lung","url":"https://clinicaltrials.gov/study/NCT05633667","created_at":"2022-12-01T15:57:15.119Z","updated_at":"2024-07-02T16:34:58.933Z","phase":"Phase 2","brief_title":"Study of Novel Treatment Combinations in Patients With Lung Cancer","source_id_and_acronym":"NCT05633667 - VELOCITY-Lung","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • PD-L1 • ALK","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy) • domvanalimab (AB154) • etrumadenant (AB928)"],"overall_status":"Recruiting","enrollment":" Enrollment 397","initiation":"Initiation: 03/16/2023","start_date":" 03/16/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-06-04"},{"id":"594eece6-f64f-4da2-846a-6e75f33b175c","acronym":"EVOKE-01","url":"https://clinicaltrials.gov/study/NCT05089734","created_at":"2021-10-22T12:53:05.373Z","updated_at":"2024-07-02T16:34:59.762Z","phase":"Phase 3","brief_title":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05089734 - EVOKE-01","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • ALK","pipe":"","alterations":" ","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 603","initiation":"Initiation: 11/17/2021","start_date":" 11/17/2021","primary_txt":" Primary completion: 11/29/2023","primary_completion_date":" 11/29/2023","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-31"},{"id":"49b56574-d546-4ca7-a49a-b03317d41c4c","acronym":"ISIdE","url":"https://clinicaltrials.gov/study/NCT05552001","created_at":"2023-09-05T19:11:08.766Z","updated_at":"2024-07-02T16:35:00.022Z","phase":"Phase 3","brief_title":"Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer","source_id_and_acronym":"NCT05552001 - ISIdE","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PGR • PD-1","pipe":" | ","alterations":" ER expression • PGR expression • ER amplification • PD-1 positive","tags":["HER-2 • ER • PGR • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression • PGR expression • ER amplification • PD-1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 10/05/2023","start_date":" 10/05/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-05-30"},{"id":"ed815c0f-e035-457c-bdd2-620951dfd038","acronym":"","url":"https://clinicaltrials.gov/study/NCT06100874","created_at":"2023-10-25T19:14:19.283Z","updated_at":"2024-07-02T16:35:00.165Z","phase":"Phase 2","brief_title":"A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)","source_id_and_acronym":"NCT06100874","lead_sponsor":"Adrienne G. Waks","biomarkers":" HER-2","pipe":" | ","alterations":" PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trodelvy (sacituzumab govitecan-hziy) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/20/2023","start_date":" 11/20/2023","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-05-30"},{"id":"5ace96de-559a-4b55-a73a-31365fb7b1ee","acronym":"ASCENT-07","url":"https://clinicaltrials.gov/study/NCT05840211","created_at":"2023-05-03T15:04:38.649Z","updated_at":"2024-07-02T16:35:00.798Z","phase":"Phase 3","brief_title":"Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy","source_id_and_acronym":"NCT05840211 - ASCENT-07","lead_sponsor":"Gilead Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 654","initiation":"Initiation: 05/08/2023","start_date":" 05/08/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-05-27"},{"id":"0efb958e-6db6-4f88-833c-4fd2bb0bae83","acronym":"","url":"https://clinicaltrials.gov/study/NCT04251416","created_at":"2024-01-27T07:17:51.583Z","updated_at":"2024-07-02T16:35:01.080Z","phase":"Phase 2","brief_title":"A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma","source_id_and_acronym":"NCT04251416","lead_sponsor":"Yale University","biomarkers":" TACSTD2","pipe":"","alterations":" ","tags":["TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-05-24"}]